Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592773 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
A Phase 2 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 2
- Development phase
- 747
- Enrollment target
NCT01592773: Clinical Trial Phase 2 study, sponsored by Forest Laboratories.
NCT01592773 is a Phase 2 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 747 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (462% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01592773, a Phase 2 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 747 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
Primary Outcome
Number of patients who experienced 1 or more Treatment Emergent Adverse Event
Interventions
- DRUG Memantine Hydrochloride (HCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Why NCT01592773 stopped before completion
NCT01592773 is an interventional study that assigns participants to a tested intervention. The registered 747 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (462% higher).
The record links to 0 conditions, and to 1 intervention - of which Memantine Hydrochloride (HCl) is the first listed.
NCT01592773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01592773 about?
NCT01592773 is a clinical study titled "Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)". The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
What is the current status of trial NCT01592773?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 747 participants. The study started on 2012-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01592773?
The interventions under investigation include: Memantine Hydrochloride (HCl) (DRUG).
Who is sponsoring clinical trial NCT01592773?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01592773's enrollment target sits among peer trials
747 44th of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia